Myriad Genetics (MYGN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Myriad Genetics (MYGN) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of $536M, trading at $5.67 on the NASDAQ. This SniperIQ fundamentals page covers Myriad Genetics's valuation, profitability (net margin -48.2%), revenue ($825M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Myriad Genetics's market cap?
Myriad Genetics (MYGN) has a market capitalization of approximately $536M, trading at $5.67 on the NASDAQ. Market cap moves with the live share price.
What is Myriad Genetics's P/E ratio?
Myriad Genetics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Myriad Genetics?
Myriad Genetics runs a net profit margin of -48.2%, a gross margin of 70.0%, and an operating margin of -46.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Myriad Genetics generate?
Myriad Genetics reported revenue of $825M for fiscal year 2025, with net income of -